Department of Medicine, Division of Infectious Diseases and Immunology
Bacterial Infections and Mycoses | Microbiology
Previously, we reported potent activity of a novel spiropyrimidinetrione, zoliflodacin, against N. gonorrhoeae isolates from symptomatic men in Nanjing, China, collected in 2013. Here, we investigated trends of susceptibilities of zoliflodacin in 986 isolates collected from men between 2014 and 2018. N. gonorrhoeae isolates were tested for susceptibility to zoliflodacin and seven other antibiotics. Mutations in gyrA, gyrB, parC, parE and mtrR genes were determined by PCR and sequencing. The MICs of zoliflodacin ranged from < /=0.002 to 0.25 mg/L; the overall MIC50s and MIC90s were 0.06 mg/L and 0.125mg/L in 2018, increasing two-fold from 2014. However, the percent of isolates with lower zoliflodacin MICs declined in each year sequentially while the percent with higher MICs increased yearly (P < /=0.00001). All isolates were susceptible to spectinomycin but resistant to ciprofloxacin (MIC > /=1 mg/L); 21.2% (209/986) were resistant to azithromycin ( > /=1 mg/L), 43.4% (428/986) were penicillinase-producing (PPNG), 26.9% (265/986) tetracycline-resistant (TRNG) and 19.4% (191/986) were multi-drug resistant (MDR) isolates. Among 202 isolates tested, all were quinolone resistant with double or triple mutations in gyrA; One hundred ninety three (193/202; 95.5%) also had mutations in parC There were no D429N/A and/or K450T mutations in GyrB identified in the 143 isolates with higher zoliflodacin MICs; a S467N mutation in GyrB was identified in one isolate. We report that zoliflodacin continues to have excellent in vitro activity against clinical gonococcal isolates, including those with high-level resistance to ciprofloxacin, azithromycin and extended spectrum cephalosporins.
N. gonorrhoeae, DNA gyrase, zoliflodacin, susceptibility
Rights and Permissions
Copyright © 2020 Le et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
DOI of Published Version
Le W, Su X, Lou X, Li X, Gong X, Wang B, Genco CA, Mueller JP, Rice PA. Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China (2014-2018). Antimicrob Agents Chemother. 2020 Dec 14:AAC.00863-20. doi: 10.1128/AAC.00863-20. Epub ahead of print. PMID: 33318010. Link to article on publisher's site
Antimicrobial agents and chemotherapy
Le W, Su X, Lou X, Li X, Gong X, Wang B, Genco CA, Mueller JP, Rice PA. (2020). Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China (2014-2018). Open Access Publications by UMMS Authors. https://doi.org/10.1128/AAC.00863-20. Retrieved from https://escholarship.umassmed.edu/oapubs/4488
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.